The drugmaker also saw revenue grow to $6.06 billion in the third quarter, compared to $5.66 billion in the same period in 2017. The growth was attributed to its strong pharmaceutical portfolio performance.
“Lilly delivered strong financial results in the third quarter. Revenue growth driven by greater use of our newest medicines, coupled with prudent expense management, led to strong earnings per share growth,” Eli Lilly Chairman and CEO David Ricks told the WSJ.
The company expects annual revenue of $24.3 billion to $24.5 billion.
More articles on pharmacy:
CVS Health posts $1.4B profit, expects Aetna deal to close by Thanksgiving
CVS pilots membership program to take on Amazon
Insys wants to sell off opioid-related assets
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
